Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Gross Margin (2020 - 2026)

GeneDx Holdings has reported Gross Margin over the past 7 years, most recently at 66.71% for Q1 2026.

  • Quarterly Gross Margin fell 42.0% to 66.71% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 69.56% through Mar 2026, up 429.0% year-over-year, with the annual reading at 69.74% for FY2025, 610.0% up from the prior year.
  • Gross Margin was 66.71% for Q1 2026 at GeneDx Holdings, down from 69.65% in the prior quarter.
  • Over five years, Gross Margin peaked at 72.4% in Q3 2025 and troughed at 81.83% in Q2 2022.
  • The 5-year median for Gross Margin is 59.93% (2024), against an average of 40.6%.
  • Year-over-year, Gross Margin tumbled -7936bps in 2022 and then skyrocketed 12034bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 26.61% in 2022, then surged by 301bps to 53.56% in 2023, then grew by 29bps to 69.22% in 2024, then grew by 1bps to 69.65% in 2025, then dropped by -4bps to 66.71% in 2026.
  • Per Business Quant, the three most recent readings for WGS's Gross Margin are 66.71% (Q1 2026), 69.65% (Q4 2025), and 72.4% (Q3 2025).